Summary of AbbVie Inc. (NYSE:ABBV) Ratings on Apr 17, 2018

April 17, 2018 - By Robert Reynolds

AbbVie Inc. (NYSE:ABBV) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.8. That’s change of 0.05, from 2017Q3’s 0.85. 42 investors sold all, 695 reduced holdings as AbbVie Inc. ratio dived. 448 increased holdings while 139 funds amassed holdings. Funds hold 1.06 billion shares thus 0.35% more from 2017Q3’s 1.06 billion shares.
Baker Boyer Bancorp reported 0.82% of its capital in AbbVie Inc. (NYSE:ABBV). Newman Dignan & Sheerar Inc holds 0.18% or 3,630 shs in its capital. M Holdings has invested 0.15% in AbbVie Inc. (NYSE:ABBV). Cetera Advsrs Lc holds 42,961 shs. California-based Huber Capital Mgmt Lc has invested 0.08% in AbbVie Inc. (NYSE:ABBV). 20,800 were accumulated by Capital Ca. Df Dent &, Maryland-based fund reported 7,533 shs. Kentucky Retirement Fund invested 0.68% in AbbVie Inc. (NYSE:ABBV). Destination Wealth holds 1.88% of its capital in AbbVie Inc. (NYSE:ABBV) for 320,552 shs. Palladium Prtnrs Ltd Liability has invested 0.98% in AbbVie Inc. (NYSE:ABBV). M Kraus And holds 67,218 shs. Moreover, Loeb Prtn Corp has 0.44% invested in AbbVie Inc. (NYSE:ABBV) for 15,430 shs. Sectoral Asset Mngmt invested in 1.03% or 85,298 shs. 1.78M were reported by Santa Barbara Asset Ltd Company. American Assets Inv Mngmt Lc owns 0.85% invested in AbbVie Inc. (NYSE:ABBV) for 46,000 shs.

AbbVie Inc. had 12 selling transactions and 0 insider purchases since October 30, 2017. This’s net activity of $49.35 million. On Wednesday, February 28 1,337 shs were sold by SALEKI-GERHARDT AZITA, worth $157,458. Shares for $9.57 million were sold by ALBAN CARLOS on Wednesday, February 28. $512,853 worth of AbbVie Inc. (NYSE:ABBV) was sold by Michael Robert A. on Wednesday, February 28. On Wednesday, February 28 the insider Schumacher Laura J sold $2.95M. Shares for $311,684 were sold by SEVERINO MICHAEL. 18,129 shs were sold by RICHMOND TIMOTHY J., worth $2.15M.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Total analysts of 13 have positions in AbbVie (NYSE:ABBV) as follows: 6 rated it a “Buy”, 1 with “Sell” and 6 with “Hold”. The positive are 46%. Since October 30, 2017 according to StockzIntelligence Inc AbbVie has 25 analyst reports. On Monday, November 20 the rating was maintained by Cowen & Co with “Buy”. The stock rating was maintained by Argus Research with “Buy” on Friday, February 2. The company rating was maintained by BMO Capital Markets on Thursday, November 16. On Friday, April 13 Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating. Jefferies has “Buy” rating and $12200 target. On Thursday, January 4 the firm has “Buy” rating given by Jefferies. On Tuesday, April 10 the firm has “Buy” rating by Piper Jaffray given. In Friday, January 26 report Jefferies maintained it with “Buy” rating and $150.0 target. On Monday, February 26 the rating was maintained by Jefferies with “Buy”. The company rating was maintained by Jefferies on Tuesday, January 16. On Thursday, March 22 SunTrust maintained the shares of ABBV in report with “Buy” rating. Listed here are AbbVie Inc. (NYSE:ABBV) PTs and latest ratings.

13/04/2018 Broker: Jefferies Rating: Buy New Target: $122.0000 Maintain
10/04/2018 Broker: Piper Jaffray Rating: Buy Maintain
06/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $135.0000
05/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $120 New Target: $102 Maintain
26/03/2018 Broker: Bank of America Rating: Hold New Target: $120.0000 Maintain
22/03/2018 Broker: SunTrust Rating: Buy New Target: $157.0000 Maintain
23/03/2018 Broker: Jefferies Rating: Buy New Target: $125.0000 Maintain
23/03/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $95 New Target: $80 Maintain
22/03/2018 Broker: Leerink Swann Rating: Hold Maintain
22/03/2018 Broker: Bernstein Rating: Hold Maintain

Its shares touched $92.95 on during the last trading session after 0.38% change.Currently AbbVie Inc. is uptrending after 39.20% change in last April 17, 2017. ABBV has 882,746 shares volume. ABBV outperformed by 27.65% the S&P 500.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide.The company has $147.48 billion market cap. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.28.17 is the P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

AbbVie Inc. (NYSE:ABBV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: